Taro Pharmaceutical (TARO) Shareholder Ajo LP Boosted Its Holding by $18.68 Million; As Supernus Pharmaceuticals (SUPN) Market Value Rose, Algert Global Increased by $425,646 Its Holding

February 17, 2018 - By Ellis Scott

Ajo Lp increased its stake in Taro Pharmaceutical (TARO) by 1787.7% based on its latest 2017Q3 regulatory filing with the SEC. Ajo Lp bought 166,757 shares as the company’s stock declined 2.08% while stock markets rallied. The institutional investor held 176,085 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $19.84 million, up from 9,328 at the end of the previous reported quarter. Ajo Lp who had been investing in Taro Pharmaceutical for a number of months, seems to be bullish on the $4.07B market cap company. The stock decreased 0.28% or $0.29 during the last trading session, reaching $101.6. About 58,801 shares traded. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 13.84% since February 17, 2017 and is downtrending. It has underperformed by 30.54% the S&P500.

Peter Algert increased its stake in Supernus Pharmaceuticals Inc (SUPN) by 21.08% based on its latest 2017Q3 regulatory filing with the SEC. Algert Global Llc bought 10,914 shares as the company’s stock rose 29.12% with the market. The hedge fund run by Peter Algert held 62,681 shares of the health care company at the end of 2017Q3, valued at $2.51 million, up from 51,767 at the end of the previous reported quarter. Algert Global Llc who had been investing in Supernus Pharmaceuticals Inc for a number of months, seems to be bullish on the $1.97B market cap company. The stock decreased 2.04% or $0.8 during the last trading session, reaching $38.35. About 448,758 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since February 17, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.

Investors sentiment decreased to 0.98 in Q3 2017. Its down 0.34, from 1.32 in 2017Q2. It dropped, as 22 investors sold SUPN shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. Barclays Public Limited Com owns 3,308 shares. J Goldman & LP stated it has 0.16% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Menta Cap Limited Liability holds 10,543 shares or 0.06% of its portfolio. The Ontario – Canada-based Royal Bank & Trust Of Canada has invested 0% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Piedmont Ltd Liability Company reported 11,044 shares. Ubs Asset Americas stated it has 246,571 shares. Jpmorgan Chase holds 0% or 1,510 shares. Teachers Retirement Of The State Of Kentucky holds 0.01% or 17,000 shares. Bnp Paribas Arbitrage holds 0% or 26,072 shares. Tower Capital Limited (Trc) stated it has 0.01% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Perigon Wealth Limited Co owns 1,674 shares. Aperio Grp Ltd, California-based fund reported 12,571 shares. Macquarie Group Inc Inc Ltd accumulated 87,188 shares. Peak6 Investments LP has 0% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 5,658 shares. Sheets Smith Wealth Management holds 0.09% or 8,671 shares in its portfolio.

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals had 36 analyst reports since August 26, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Thursday, August 3. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Neutral” rating given on Monday, July 17 by PiperJaffray. The rating was downgraded by Stifel Nicolaus on Tuesday, September 19 to “Hold”. The rating was downgraded by Piper Jaffray on Monday, July 18 to “Neutral”. Stifel Nicolaus maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Monday, July 17 with “Buy” rating. The company was maintained on Tuesday, January 2 by Stifel Nicolaus. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Hold” rating given on Thursday, August 3 by Piper Jaffray. Cowen & Co maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating on Monday, October 23. Cowen & Co has “Buy” rating and $50.0 target. B. Riley & Co maintained the shares of SUPN in report on Wednesday, November 8 with “Buy” rating. The firm has “Hold” rating given on Wednesday, August 26 by Zacks.

Since August 16, 2017, it had 0 buys, and 10 insider sales for $15.31 million activity. Bhatt Padmanabh P. sold 5,000 shares worth $249,303. $630,650 worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was sold by Vaughn Victor on Tuesday, January 9. The insider Schwabe Stefan K.F. sold $4.43 million.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>